Effect of Valsartan on Systemic Right Ventricular Function A Double-Blind, Randomized, Placebo-Controlled Pilot Trial

T van der Bom; MM Winter; BJ Bouma; M Groenink; HW Vliegen; PG Pieper; APJ van Dijk; GT Sieswerda; Jolien Roos - Hesselink; AH Zwinderman; BJM Mulder

doi:10.1161/CIRCULATIONAHA.112.135392

Effect of Valsartan on Systemic Right Ventricular Function A Double-Blind, Randomized, Placebo-Controlled Pilot Trial

T van der Bom, MM Winter, BJ Bouma, M Groenink, HW Vliegen, PG Pieper, APJ van Dijk, GT Sieswerda, Jolien Roos - Hesselink, AH Zwinderman, BJM Mulder

Cardiology

Research output: Contribution to journal › Article › Academic › peer-review

169 Citations (Scopus)

Abstract

Background-The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. Methods and Results-We conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo in patients with a systemic right ventricle caused by congenitally or surgically corrected transposition of the great arteries. The primary end point was change in right ventricular ejection fraction during 3-year follow-up, determined by cardiovascular magnetic resonance imaging or, in patients with contraindica Conclusions-There was no significant treatment effect of valsartan on right ventricular ejection fraction, exercise capacity, or quality of life. Valsartan was associated with a similar frequency of significant clinical events as placebo. Small but significant differences between valsartan and placebo were present for change in right ventricular volumes and mass. Clinical Trial Registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN52352170. (Circulation. 2013; 127: 322-330.)

Original language	Undefined/Unknown
Pages (from-to)	322-+
Journal	Circulation
Volume	127
Issue number	3
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.112.135392
Publication status	Published - 2013

Research programs

EMC COEUR-09

Access to Document

10.1161/CIRCULATIONAHA.112.135392

http://hdl.handle.net/1765/60910

Cite this

van der Bom, T., Winter, MM., Bouma, BJ., Groenink, M., Vliegen, HW., Pieper, PG., van Dijk, APJ., Sieswerda, GT., Roos - Hesselink, J., Zwinderman, AH., & Mulder, BJM. (2013). Effect of Valsartan on Systemic Right Ventricular Function A Double-Blind, Randomized, Placebo-Controlled Pilot Trial. Circulation, 127(3), 322-+. https://doi.org/10.1161/CIRCULATIONAHA.112.135392

@article{4d0889aa6e004718815e67d2b4fd8fae,

title = "Effect of Valsartan on Systemic Right Ventricular Function A Double-Blind, Randomized, Placebo-Controlled Pilot Trial",

abstract = "Background-The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. Methods and Results-We conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo in patients with a systemic right ventricle caused by congenitally or surgically corrected transposition of the great arteries. The primary end point was change in right ventricular ejection fraction during 3-year follow-up, determined by cardiovascular magnetic resonance imaging or, in patients with contraindica Conclusions-There was no significant treatment effect of valsartan on right ventricular ejection fraction, exercise capacity, or quality of life. Valsartan was associated with a similar frequency of significant clinical events as placebo. Small but significant differences between valsartan and placebo were present for change in right ventricular volumes and mass. Clinical Trial Registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN52352170. (Circulation. 2013; 127: 322-330.)",

author = "{van der Bom}, T and MM Winter and BJ Bouma and M Groenink and HW Vliegen and PG Pieper and {van Dijk}, APJ and GT Sieswerda and {Roos - Hesselink}, Jolien and AH Zwinderman and BJM Mulder",

year = "2013",

doi = "10.1161/CIRCULATIONAHA.112.135392",

language = "Undefined/Unknown",

volume = "127",

pages = "322--+",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "3",

}

van der Bom, T, Winter, MM, Bouma, BJ, Groenink, M, Vliegen, HW, Pieper, PG, van Dijk, APJ, Sieswerda, GT, Roos - Hesselink, J, Zwinderman, AH & Mulder, BJM 2013, 'Effect of Valsartan on Systemic Right Ventricular Function A Double-Blind, Randomized, Placebo-Controlled Pilot Trial', Circulation, vol. 127, no. 3, pp. 322-+. https://doi.org/10.1161/CIRCULATIONAHA.112.135392

TY - JOUR

T1 - Effect of Valsartan on Systemic Right Ventricular Function A Double-Blind, Randomized, Placebo-Controlled Pilot Trial

AU - van der Bom, T

AU - Winter, MM

AU - Bouma, BJ

AU - Groenink, M

AU - Vliegen, HW

AU - Pieper, PG

AU - van Dijk, APJ

AU - Sieswerda, GT

AU - Roos - Hesselink, Jolien

AU - Zwinderman, AH

AU - Mulder, BJM

PY - 2013

Y1 - 2013

N2 - Background-The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. Methods and Results-We conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo in patients with a systemic right ventricle caused by congenitally or surgically corrected transposition of the great arteries. The primary end point was change in right ventricular ejection fraction during 3-year follow-up, determined by cardiovascular magnetic resonance imaging or, in patients with contraindica Conclusions-There was no significant treatment effect of valsartan on right ventricular ejection fraction, exercise capacity, or quality of life. Valsartan was associated with a similar frequency of significant clinical events as placebo. Small but significant differences between valsartan and placebo were present for change in right ventricular volumes and mass. Clinical Trial Registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN52352170. (Circulation. 2013; 127: 322-330.)

AB - Background-The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. Methods and Results-We conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo in patients with a systemic right ventricle caused by congenitally or surgically corrected transposition of the great arteries. The primary end point was change in right ventricular ejection fraction during 3-year follow-up, determined by cardiovascular magnetic resonance imaging or, in patients with contraindica Conclusions-There was no significant treatment effect of valsartan on right ventricular ejection fraction, exercise capacity, or quality of life. Valsartan was associated with a similar frequency of significant clinical events as placebo. Small but significant differences between valsartan and placebo were present for change in right ventricular volumes and mass. Clinical Trial Registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN52352170. (Circulation. 2013; 127: 322-330.)

U2 - 10.1161/CIRCULATIONAHA.112.135392

DO - 10.1161/CIRCULATIONAHA.112.135392

M3 - Article

C2 - 23247302

SN - 0009-7322

VL - 127

SP - 322-+

JO - Circulation

JF - Circulation

IS - 3

ER -